warning about possible hepatotoxicity in diabetics taking Rezulin (troglitazone)

    Parke-Davis is warning about possible hepatotoxicity in diabetics taking Rezulin (troglitazone).

    This is important. Rezulin has been given to about half a million patients since it came out last January.

    But now there are 35 reports of liver damage...resulting in one liver transplant and one death.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote